Press Releases

Print

Receive E-mail Alerts

Click here to receive press releases by email from the company.

Press Releases

Date Title
11/17/2016 GlobeImmune Announces Updates
07/05/2016 GlobeImmune Announces Delisting and Deregistration of Common Stock
05/12/2016 GlobeImmune Announces Updates and Financial Results for First Quarter 2016
03/16/2016 GlobeImmune Announces Updates and Financial Results for Full Year 2015
11/13/2015 GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
08/14/2015 GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
08/13/2015 GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
08/04/2015 Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
08/04/2015 UPDATE – Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
06/10/2015 GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring
05/27/2015 GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients
05/14/2015 GlobeImmune Announces First Quarter 2015 Results and Corporate Highlights
04/22/2015 GlobeImmune Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute
03/17/2015 GlobeImmune Announces Program Updates and Financial Results for Full Year 2014
03/02/2015 GlobeImmune to Present at the 27th Annual ROTH Conference
02/03/2015 GlobeImmune to Present at the 17th Annual BIO CEO & Investor Conference
11/12/2014 GlobeImmune Announces Third Quarter 2014 Financial Results
10/17/2014 Updated Chordoma Data From Phase 1 Study of GI-6301 Presented at 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting
09/30/2014 GlobeImmune to Present at the 13th Annual BioInvestor Forum
09/18/2014 GlobeImmune to Present at the 21st Annual NewsMakers in the Biotechnology Industry Investment Conference
09/03/2014 GlobeImmune to Present at the Aegis Capital Corp. 2014 Healthcare Conference
07/01/2014 GlobeImmune Announces Pricing of Initial Public Offering